Want to see IN:JBCHEPHARM full AI Analyst Report?
JBCHEPHARM Stock Chart & Stats
₹1847.80
-₹0.05(>-0.01%)
At close: 4:00 PM EST
₹1847.80
-₹0.05(>-0.01%)
Day’s Range― - ―
52-Week Range₹1,603.05 - ₹2,330.00
Previous CloseN/A
Volume153.25K
Average Volume (3M)2.67K
Market Cap
₹372.25B
Enterprise Value₹351.10B
Total Cash (Recent Filing)₹9.01B
Total Debt (Recent Filing)₹409.10M
Price to Earnings (P/E)51.3
Beta0.54
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.86%
Share Statistics
EPS (TTM)46.08
Shares Outstanding160,558,700
10 Day Avg. Volume4,569
30 Day Avg. Volume2,671
Financial Highlights & Ratios
PEG Ratio7.16
Price to Book (P/B)7.80
Price to Sales (P/S)7.82
P/FCF Ratio51.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)60.69
Revenue Forecast (FY)₹47.09B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage materially reduces financial risk and preserves strategic flexibility. With debt near‑negligible versus equity, management can fund capex, R&D, or selective M&A without heavy refinancing, supporting durable operations and resilience through industry cycles.
Improving Cash GenerationConsistently positive operating cash flow and a recent rebound in free cash flow underpin internal funding for growth, working capital, and shareholder returns. Strong cash conversion versus net income enhances long‑term self‑funding capacity and reduces reliance on external capital.
Multi-year Revenue Expansion And ProfitabilitySustained revenue scale and mid‑to‑high teens margins indicate durable demand and efficient operations. Broad product mix across formulations and exports provides market diversification, supporting continued cash earnings and competitive positioning over the medium term.
Bears Say
Recent Slowdown In Revenue GrowthA deceleration to low single‑digit top‑line growth reduces the pace at which the business can scale margins and earnings. If persistent, slower revenue expansion may force trade‑offs between margin protection, reinvestment, and market share maintenance in competitive branded generics and export markets.
Margin VariabilityNotable swings in gross and operating margins suggest sensitivity to product mix, pricing pressure, or input‑cost shifts. Variable margins undermine earnings predictability and can complicate capital allocation, making long‑term cash flow forecasts and sustainable payout policies more uncertain.
Historical Free Cash Flow VolatilityEpisodes of materially negative free cash flow indicate operational or working‑capital strain during investment cycles. Even with a recent recovery, past volatility highlights execution risk: future capex, inventory swings or customer collections could reintroduce cash pressure and constrain strategic choices.
JB Chemicals & Pharmaceuticals Ltd. News
JBCHEPHARM FAQ
What was JB Chemicals & Pharmaceuticals Ltd.’s price range in the past 12 months?
JB Chemicals & Pharmaceuticals Ltd. lowest stock price was ₹1603.05 and its highest was ₹2330.00 in the past 12 months.
What is JB Chemicals & Pharmaceuticals Ltd.’s market cap?
JB Chemicals & Pharmaceuticals Ltd.’s market cap is ₹372.25B.
When is JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date?
JB Chemicals & Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.
How were JB Chemicals & Pharmaceuticals Ltd.’s earnings last quarter?
JB Chemicals & Pharmaceuticals Ltd. released its earnings results on May 11, 2026. The company reported ₹8.25 earnings per share for the quarter, missing the consensus estimate of ₹9.9 by -₹1.65.
Is JB Chemicals & Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts JB Chemicals & Pharmaceuticals Ltd.’s price is currently Overvalued.
Does JB Chemicals & Pharmaceuticals Ltd. pay dividends?
JB Chemicals & Pharmaceuticals Ltd. pays a Semiannually dividend of ₹9.3 which represents an annual dividend yield of 0.86%. See more information on JB Chemicals & Pharmaceuticals Ltd. dividends here
What is JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate?
JB Chemicals & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JB Chemicals & Pharmaceuticals Ltd. have?
JB Chemicals & Pharmaceuticals Ltd. has 160,558,700 shares outstanding.
What happened to JB Chemicals & Pharmaceuticals Ltd.’s price movement after its last earnings report?
JB Chemicals & Pharmaceuticals Ltd. reported an EPS of ₹8.25 in its last earnings report, missing expectations of ₹9.9. Following the earnings report the stock price went up 2.6%.
Which hedge fund is a major shareholder of JB Chemicals & Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:JBCHEPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JB Chemicals & Pharmaceuticals Ltd.
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
Eris Lifesciences Ltd
―
IPCA Laboratories Limited
―
Wockhardt Limited
―